What is Minomic?
Minomic is an Australian-based biotechnology enterprise dedicated to the development and commercialization of innovative diagnostic tests for solid tumors. The company has gained significant market traction with its flagship product, MiCheck Prostate, a blood-based diagnostic tool that leverages patented monoclonal antibodies and specific biomarkers. By providing a clinically actionable risk score, the platform assists urologists in making more informed biopsy decisions, thereby reducing unnecessary procedures and improving patient outcomes. The company maintains a robust intellectual property portfolio, which serves as the foundation for its ongoing expansion into the prostate, bladder, and pancreatic cancer diagnostic markets.
How much funding has Minomic raised?
Minomic has raised a total of $3.7M across 1 funding round:
Private Equity
$3.7M
Private Equity (2016): $3.7M, investors not publicly disclosed
Key Investors in Minomic
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Minomic?
With this major enterprise-level funding, Minomic is poised to scale its operations across key international markets, including the United States and Australia. The strategic roadmap likely involves expanding the clinical utility of the MiCheck platform and deepening its intellectual property moat through continued research and development. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward securing broader clinical adoption and establishing high-value partnerships with healthcare providers and diagnostic laboratories. This capital deployment will be instrumental in navigating the regulatory landscape and scaling the commercial infrastructure required to support the widespread implementation of its diagnostic solutions in the global oncology market.
See full Minomic company page
